

THE DIFFERENCE OF
BREAKING THROUGH BARRIERS
WITH VIBRANCE

ENABLING GREATER EXPERIMENTAL
INSIGHTS WITH THE POWER OF
BD HORIZON™ RED 718 REAGENTS



Achieve your resolution goals today >



World Malaria Day 2009: What Malaria Knows about the Immune System That Immunologists Still Do Not

This information is current as of April 13, 2021.

Susan K. Pierce and Louis H. Miller

J Immunol 2009; 182:5171-5177; ;
doi: 10.4049/jimmunol.0804153
<http://www.jimmunol.org/content/182/9/5171>

References This article **cites 58 articles**, 24 of which you can access for free at:
<http://www.jimmunol.org/content/182/9/5171.full#ref-list-1>

Why *The JI*? [Submit online.](#)

- **Rapid Reviews! 30 days*** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

**average*

Subscription Information about subscribing to *The Journal of Immunology* is online at:
<http://jimmunol.org/subscription>

Permissions Submit copyright permission requests at:
<http://www.aai.org/About/Publications/JI/copyright.html>

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
<http://jimmunol.org/alerts>

The Journal of Immunology is published twice each month by
The American Association of Immunologists, Inc.,
1451 Rockville Pike, Suite 650, Rockville, MD 20852
Copyright © 2009 by The American Association of
Immunologists, Inc. All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.



World Malaria Day 2009: What Malaria Knows about the Immune System That Immunologists Still Do Not

Susan K. Pierce^{1*} and Louis H. Miller[†]

Malaria kills >1 million children each year, and there is little doubt that an effective vaccine would play a central role in preventing these deaths. However, the strategies that proved so successful in developing the vaccines we have today may simply not be adequate to confront complex, persistent infectious diseases, including malaria, AIDS, and tuberculosis. We believe that the development of a highly effective vaccine will require a better understanding of several features of the immune response to malaria. At the top of the list is the complex and ancient relationship between the parasite that causes malaria and the immune system that enables the parasite to persist in an otherwise functional immune system. A close second is the antigenic targets in malaria and how to overcome the enormous polymorphism of these targets. Meeting these challenges represents a call to arms of basic immunologists to advance our knowledge of malaria immunity. *The Journal of Immunology*, 2009, 182: 5171–5177.

Why another review of malaria immunity

A recent PubMed search for malaria and immunity retrieved >30 reviews on the topic, many excellent. What compelled us to write another? What we hope to accomplish in this article is to present to the immunology community the challenges of developing a malaria vaccine. We do so in an effort to recruit expert immunologists to bring their fresh perspective to this ancient and deadly disease. We point out the enormity of the problem, the current state of vaccine development, and what we will need to know about malaria and the human immune system to develop a highly effective vaccine. We invite members of the immunology community to consider what they see as gaps in our knowledge of malaria immunity and, better yet, to roll up their sleeves and help fill in those gaps.

We need a vaccine because malaria is a killer and unlikely to be controlled without one

Malaria is an infectious disease caused by obligate intracellular Apicomplexa parasitic protozoa that are members of the genus *Plasmodium*. The most deadly species, *Plasmodium falciparum*, prevails in Africa. The enormous impact of malaria on mortality

in humans can readily be appreciated by considering the high prevalence in Africa of the hemoglobin S allele (Hb-S). Despite the fact the Hb-S homozygosity causes sickle cell anemia and death in children in West Africa, Hb-S is maintained at a gene frequency of nearly 18% because, in the heterozygous state, Hb-SA confers protection against severe malaria (1). Calculations of the mortality from malaria that is required to maintain this high frequency of Hb-S in Africa indicate that nearly half of all deaths by any cause in Africa were due to *P. falciparum* infection (1) before the introduction of the inexpensive antimalarial drug chloroquine. Thus, malaria is almost unimaginably deadly.

Can we control malaria without a vaccine? *P. falciparum* is transmitted from person to person by the bite of the female *Anopheles* mosquitoes *Anopheles gambiae* and *Anopheles funestus* in Africa. *A. gambiae* is a highly efficient, highly adapted vector that feeds nearly exclusively on humans and has a long lifespan, >30 days. As a consequence, *A. gambiae* mosquitoes feeding on a single infected individual are able to transmit malaria to hundreds of others. Any means of limiting the ability of mosquitoes to transmit the parasite limits the spread of *P. falciparum*, including the use of bed nets and insecticides. *P. falciparum* is also sensitive to several drugs when in the human host. There is no question today that artemisinin-based combination therapy is highly effective in reducing severe disease (2). However, insecticides and antimalarial drugs are predicted to be only partially effective in controlling disease in the long run due in large part to the inevitable acquisition of resistance. The enormous impact of drug resistance on disease is illustrated by the coincidence of the appearance of chloroquine resistance in parasites over a 3-year period in the 1980s in Africa with a huge increase in the malaria mortality rate from 4.8% to 15.3% in one hospital in Zaire (3). Difficulties with both delivery and compliance in the use of bed nets and antimalarial drugs also decrease the effectiveness of these as tools in disease control. Thus, the development of a malarial vaccine that could be delivered to infants along with other childhood vaccines has become a top public health priority. We believe that malaria will remain a shadow over African children, taking >1 million young lives a year until an effective vaccine that confers protection from disease is available.

^{*}Laboratory of Immunogenetics and [†]Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852

Received for publication January 16, 2009. Accepted for publication March 5, 2009.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Address correspondence and reprint requests to Dr. Susan K. Pierce, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Twinbrook II, 12441 Parklawn Drive, Room 200B, Mail Stop Code 8180, Rockville, MD 20852. E-mail address: spierce@nih.gov

The special challenges of developing a malarial vaccine

There are a large number of successful vaccines in use for other diseases, thus raising the question “how is malaria different?” The diseases for which we currently have effective vaccines, including polio, diphtheria, tetanus, measles, and pertussis, are caused by pathogens or toxins of the pathogens to which exposure confers life-long sterile immunity. Indeed, it was possible to develop a vaccine for smallpox >200 years ago based only on the principle that exposure to the pustules of cowpox conferred resistance to smallpox without any knowledge of either the organism that caused the disease or the immune response to it. However, malaria is different. *P. falciparum* infections can persist for months and individuals are always susceptible to reinfection. *P. falciparum* appears to both evade and disable the immune system by a variety of mechanisms that allow it to persist in the host. Suffice it to say that despite an enormous research effort and expense, there are still no vaccines available for “chronic” infectious diseases, including malaria.

Several features of malaria and the immune response to it suggest that the parasite and the immune system interact through a myriad of complex mechanisms that ultimately result in the inability of an otherwise functional immune system to eliminate the parasite and resist subsequent infections. In considering the interplay of the parasite and the immune system, it is important to consider that *P. falciparum* is estimated to be >100,000 years old (4), as old as humans, suggesting that the human immune system and the parasite coevolved. The enormous selective pressure imposed by malaria mortality described above predicts that any mutation in the human genome that confers protection against severe disease and death would be rapidly selected for and fixed in the human population. Indeed, malaria has had more impact than any other pathogen in shaping the human genome (5, 6). It is entirely possible that malaria has shaped the immune mechanisms that come into play at the interface of the parasite and human immune system, permitting chronic and recurrent infections by the parasite. The parasite’s survival is absolutely dependent on its ability to persist in the human host and to be transmitted. In areas of seasonal transmission, as is the case for most of West Africa, the mosquitoes do not transmit during the six-month dry season, and so survival of the parasite depends on its ability to persist in the human host for months. It seems that coadaptation of the parasite and the human host has ensured that the human immune system does not efficiently clear the parasite. Presumably, the persistence of the parasite has some advantage to the host, perhaps by reducing risk of disease (7, 8). Thus, an effective vaccine may need to disrupt the balance between the parasite and the human immune system that has evolved to benefit both.

The clinical picture of malaria in young children and the natural acquisition of resistance

Children are infected with *P. falciparum* sporozoites by the bite of an infected mosquito (Fig. 1). A small number of injected sporozoites enter the blood and travel to the liver where they invade and replicate within hepatocytes. There are no symptoms during this phase of the infection. The sporozoites in the liver expand enormously, up to 40,000-fold, and differentiate into merozoites. The merozoites are released from infected liver cells and enter the bloodstream, inundating the immune system with a huge bolus of parasites that infect RBC. The merozoites replicate in red cells

and are released by rupture of the red cell. The released merozoites infect new RBC, establishing a cycle of invasion, replication, and rupture. Parasitemia often exceeds densities of 50,000 or more parasites per microliter of blood. A number of parasite products are released upon red cell lysis and are linked to the symptoms of mild disease: headaches, chills, fever, and lethargy. In young children under the age of five, the infection can progress to severe disease. Severe malaria, which accounts for the high mortality among young children, includes cerebral malaria (9), acidosis (10), and severe anemia combined with acidosis (11). For cerebral malaria the symptoms are associated with sequestration of the infected RBC in the brain (9), causing inflammation (Fig. 1). At present, the mechanisms by which parasite sequestration leads to severe malaria and death are only poorly understood. Clearly, understanding these mechanisms is an important priority in malaria immunology.

What is the nature of naturally acquired resistance to disease in malaria endemic areas? Seroepidemiological studies indicate that immunity to malaria is slow to develop, taking several years in sub-Saharan Africa despite repeated bites from infected mosquitoes. Young children appear to have insufficient immunity to infection and to mild and severe disease. Children between the ages of 5 and 10 develop an immunity to severe disease but still suffer from mild disease, and it is not until adolescence that immunity to disease is established. Immunity to infection is never acquired, and adults living in malaria endemic areas, although rarely sick from malaria, often carry the parasite albeit at lower levels than children. Collectively, these observations suggest that immunity to severe disease, mild disease, and infection may involve different immune mechanisms. In part, optimism that a malaria vaccine is possible comes from the fact that, although the human immune system does not prevent infection, immunity to both severe and mild disease is eventually acquired through continued natural exposure to the parasite. However, a vaccine might need to evoke protection against disease by mechanisms that do not have dominant roles in naturally acquired immunity. For example, natural immunity is not acquired at the pre-erythrocytic stage of infection (12); nonetheless, the leading vaccine candidate RTS,S, which is under development at Glaxo-SmithKline, targets the pre-erythrocytic stage (13). In this context it will also be critical that RTS,S induces life-long immunity, as presumably there will be no natural boosting from infection.

*The *P. falciparum* life cycle and vaccine targets*

Pre-erythrocytic vaccines. Individuals are initially infected by *P. falciparum* sporozoites that invade hepatocytes. A small number of sporozoites present in the salivary glands of infected mosquitoes are injected into the skin as the mosquito takes a blood meal. These cross the endothelium of blood capillaries, enter the blood, and travel to the liver where they invade hepatocytes. Recent evidence in mice shows that sporozoites also travel to the local draining lymph node, where T cell priming occurs (14). In hepatocytes, each sporozoite undergoes extensive replication within a parasite-derived vacuole, essentially walling off the parasite from the liver cell cytoplasm. A set of parasite proteins are selectively transported across the vacuolar membrane into the




FIGURE 1. The life cycle of *P. falciparum*. Humans are infected with *P. falciparum* haploid sporozoites by the bite of an infected female mosquito. The sporozoites, present in the infected mosquito's salivary glands, are injected into the skin as the mosquito probes the skin preparing to take a blood meal (*a*). Only a small number of sporozoites are injected, and these enter the blood stream (*b*) and travel to the liver where they invade hepatocytes (*c*). Sporozoites also enter the draining lymphatics and travel to the draining lymph node (*d*) where T cell priming has been reported to occur. In a hepatocyte, the parasite replicates and differentiates, giving rise to many thousands of merozoites that are released into the blood (*e*). Merozoites infect RBC and within 12 h remodel the RBC and its membrane, thereby facilitating growth of the parasites and allowing the infected RBC to bind to the endothelium in different tissues, avoiding clearance in the spleen. In severe disease, parasitized RBC attach to endothelial cells in various tissues, for example in the brain, causing cerebral malaria (*g*). Shown is a ring hemorrhage around a small vessel in the brain. In the RBC merozoites replicate, giving rise to up to 24 new merozoites per RBC (*f*). The released merozoites infect new RBC, and the cycle of RBC invasion, replication, rupture, and reinvasion continues until treatment with antimalarials or control by an immune response. At some point in a poorly understood process a subset of merozoites differentiate into male and female gametocytes (*h*). These gametocytes, taken up in the blood meal by the mosquito, develop into gametes that fuse in the midgut of the mosquito to form a motile zygote, the ookinete, where meiosis occurs (*i*). The ookinete crosses the midgut wall and forms an oocyst that develops into sporozoites that enter the mosquito salivary gland, thereby completing the cycle.

cytosol and, in the case of the circumsporozoite (CS)² protein, into the nucleus where the CS protein influences the expression of hundreds of liver cell genes, creating a hospitable environ-

ment for parasite growth (15). Immunity to the pre-erythrocytic stage of the infection is, for the most part, not acquired naturally (16), indicating that the small number of sporozoites and infected liver cells are not readily detected by the immune system. Nonetheless, several vaccine candidates, including the leading vaccine candidate RTS,S, target the pre-erythrocytic

² Abbreviations used in this paper: CS, circumsporozoite; AMA1, apical membrane Ag 1; PfEMP1, *P. falciparum* erythrocyte membrane protein 1; SLE, systemic lupus erythematosus.

stage. Given that there is little natural immunity to the pre-erythrocyte stage, what is the evidence that this stage of malarial infection is a viable vaccine target? Landmark experiments reported in the late 1960s showed in mice (17) that inoculation with a large number of irradiated sporozoites resulted in complete protective immunity for 6 mo against sporozoite challenge. Immunity appears to involve both CD4⁺ and CD8⁺ T cells and Abs. Based to a large extent on these observations, several pre-erythrocyte stage vaccines have been tested both in nonimmune volunteers challenged with bites of *P. falciparum*-infected mosquitoes (phase IIa trials) and in the field in malaria endemic areas (phase IIb trials). Thus far, several vaccines have failed in phase IIa and IIb trials, for example the DNA-based vaccines that contained multiple T cell epitopes of pre-erythrocyte-stage Ags including CS (18). In phase IIa trials of the CS protein-based RTS,S vaccine (19), the most advanced malaria vaccine candidate, protection was achieved in 30–50% of vaccinated volunteers. The results of the phase IIb trials of RTS,S seem to be promising, showing a delayed time to infection in children lasting for 18 mo (13) and some efficacy in infants. In another phase IIb trial there was a reduction in clinical malaria (20). Additional pre-erythrocytic vaccines are in development that have not yet been tested in human trials, including one consisting of whole irradiated sporozoites.

Asexual erythrocytic vaccines. Merozoites released from infected liver cells enter the bloodstream and infect RBC. Parasite-specific Abs have been shown to have a crucial role in controlling disease at this stage. The transfer of Abs from immune adults to African children with severe clinical malaria and high parasitemia with malaria resulted in a significant decrease in parasite levels and disease (21). Based on these observations, several merozoite products (22) are under development as erythrocytic stage vaccines. Ideally, the selection of candidate Ags for the development of an erythrocytic stage vaccine would be guided by knowledge of the nature of the Abs that confer naturally acquired protection in immune adults. Unfortunately, at present we simply do not know the specificity, affinity, or isotype of Abs that confer protection against disease. The *P. falciparum* genome encodes an estimated 5,600 proteins, making the identification of the targets of protective immunity a daunting task. In the absence of such knowledge, what are the rationale targets for protective antibodies? Blood-stage infection involves the attachment of the merozoite through various erythrocyte-binding proteins to any of several receptors on the surface of the RBC (23, 24). On the face of it, these receptors would seem to be good vaccine targets. However, *P. falciparum* uses many, often functionally redundant receptors to invade RBC so that Abs to only one receptor may not block blood-stage infection. The only bona fide parasite receptor for red cells currently under development as a vaccine is based on the *P. falciparum* protein erythrocyte-binding Ag 175, which is a receptor for glycophorin A on RBC (25). In addition, several recombinant merozoite membrane proteins of unknown function, including merozoite surface proteins and apical membrane Ag 1 (AMA1), have been tested or are planned to be tested alone and in combination in phase II clinical trials. To date only one vaccine has shown some protection against the blood stage, and it contains a combination of merozoite proteins (26). Three proteins released in large quantities from the lysed RBC, SERA5, GLURP, and MSP3, are also under

development as vaccines. The rationale for these vaccines is based, in part, on the observation that Ag-Ab complexes bound to monocyte Fc receptors trigger the release of as yet uncharacterized products that are inhibitory to parasite growth in infected RBC, a process termed Ab-dependent cellular inhibition (27). Lysed RBC also lead to the release of a variety of inflammation-inducing products that result in the symptoms of malaria, including the parasite toxin glycosylphosphatidylinositol, which has been proposed as a target of an anti-inflammatory vaccine for malaria (28).

In addition to Ab responses, the innate system and particularly inflammation plays crucial roles in controlling blood-stage malaria; but for the most part, the potential importance of this inflammatory process has not been taken into consideration in vaccine design. In mice, the initial malaria infection can be controlled by a strong proinflammatory response that is rapidly down-regulated (29, 30), presumably to limit the pathology associated with inflammation. In humans, an important aspect of immunity to disease might be the ability to mount a proinflammatory response as well as the ability to rapidly control the inflammatory response. The first insights into the regulation of malaria-induced proinflammatory responses in humans come from clinical records of individuals infected with *P. falciparum* as a treatment for neurosyphilis. These records provide evidence that humans learn to control the inflammation quickly despite continued parasitemia (7). More recent studies have shown a complex relationship between inflammatory cytokines and severe disease in malaria (31, 32) and suggested a possible link between the initial innate response to infection and the outcome of disease (33). However, in no case has causality between disease outcome and cytokine production been proven. Certainly, it will be essential to understand the role of the innate immune system and inflammation in severe disease in developing a malaria vaccine.

How P. falciparum evades and disables the immune response

Despite the large number of potential Ag targets, malaria vaccine development might be confounded by the immune evasion strategies of the parasite. Whether this will be a serious problem depends to a large extent on the cellular and molecular mechanisms that underlie the effect of *P. falciparum* on the immune system and whether the mechanisms that *P. falciparum* uses to evade or disable the natural immune response will also disrupt immunity established by vaccination. At present we simply do not know enough about such mechanisms to evaluate their potential impact.

Immune evasion. *P. falciparum* uses both antigenic variation and polymorphism to avoid immune recognition, mainly in the blood stage of the life cycle. Rapid antigenic variation is achieved through the *var* genes. The *var* gene products, *P. falciparum* erythrocyte membrane protein 1 (PfEMP1) proteins, are expressed on the surfaces of infected RBC and are essential for binding the endothelium and sequestering the infected RBC to avoid their removal in the spleen (9). Each *P. falciparum* genome contains ~60 antigenically distinct *var* genes that individual parasites express one at a time. However, within a clonal parasite population there is a constant low level of switching between the expressed *var* genes (34). Abs elicited to the predominant *var* gene products that are expressed by the infecting parasite clone block sequestration, thereby decreasing the number of infected RBC and the parasite load. Immune elimination

of these parasites allows the expansion of parasite clones that have switched to express different *var* genes against which existing Abs have little effect. Abs specific for the new dominant *var* variant are then induced, which eliminate the infected RBC and allow another switched parasite clone to expand (9). The education of the immune system to recognize all of the numerous *var* genes is a slow process that accounts, to a large extent, for the late acquisition of adaptive immunity to disease in endemic areas (35). The enormous antigenic variation of PfEMP1 proteins makes them poor vaccine candidates at present unless, for example, a subset of *var* genes that causes cerebral malaria is identified.

There is, however, one *var* gene that may be a good vaccine candidate for pregnancy-associated malaria. Pregnancy-associated malaria is a devastating disease in which RBC are infected by parasites expressing one particular PfEMP1, VAR2CSA, which has the unique ability to bind to chondroitin sulfate A on placental syncytiotrophoblast cells (36, 37). VAR2CSA-expressing parasites sequester in the placenta where they cause inflammation and, in many cases, death of the mother and dangerously low birth weights in infants. During first pregnancies in endemic areas, women are highly susceptible to placental malaria but develop rapid protective immunity to VAR2CSA, such that placental malaria is only problematic in women during their first or second pregnancy (38). The VAR2CSA protein is a highly attractive candidate for a vaccine for placental malaria and, based on the epidemiological data, the first fully protective malaria vaccine developed might well be for placental malaria. At present, efforts to develop a placental malaria vaccine are still in the preclinical stages.

The 60 *var* genes, although forming a significant component of the *P. falciparum* immune-evasion armory, are not the only parasite products against which immunity is acquired. Indeed, individuals are eventually able to control infections despite *var* gene switching. Unfortunately, these additional immune targets are themselves highly polymorphic, and the immunity acquired to one parasite clone does not protect against infection with another clone. The parasite's AMA1 is a good example. Immune responses to AMA1 can control disease in animal models (39), which makes AMA1 an important vaccine candidate. However, AMA1 is highly polymorphic with >150 haplotypes, all of which seem to be present in all malaria-endemic regions (40). Ab responses are generally haplotype specific, such that Abs specific for one AMA1 haplotype that block invasion of RBC only partially block invasion by parasites expressing another haplotype. How can such high degrees of polymorphism be addressed in vaccine development? Recently, a detailed population structure analysis of the relationship between AMA1 haplotypes indicates that they can, in fact, be grouped into six subpopulations and that vaccination with one member of a subpopulation protects against parasites expressing other members of that subpopulation (40). So, it might be possible to combine as few as six AMA1 haplotypes into a vaccine that would be effective in protecting against all parasites. Other approaches are indicated by the structure of AMA1, which shows that most of the polymorphic residues are concentrated on one face of the protein, meaning that the other face is highly conserved. The highly conserved face appears to be a vaccine target, as a mAb that binds to this region blocks invasion by all parasites regardless of AMA1 haplotype (41). The conserved face might be immunogenic if, for example, the AMA1 could be engi-

neered to eliminate the apparently immunodominant polymorphic residues on the other face and focus the response to the conserved face.

The very real challenge for vaccine design posed by the antigenic variation and polymorphism of many of the proteins of *P. falciparum* raises the question of whether there is an as yet unidentified group of nonvariant Ags that would induce full protection. How would one identify such Ags? One approach is through "reverse vaccinology" as pioneered for bacterial vaccines (42). Reverse vaccinology is an approach to develop vaccines starting from genomic information rather than growing the causative microorganism. In this approach criteria are set for potential vaccine candidates that can be discerned from genomic information alone (for example, membrane expression or time expressed in the life cycle), and candidates are tested for their ability to evoke protective responses. New vaccine candidates could also be discovered by taking advantage of the known *P. falciparum* genome in another way, namely to create protein microarrays (43) that contain most if not all *P. falciparum* gene products that can then be used to screen sera from children in endemic areas to correlate the production of Abs specific for particular gene products with the acquisition of protection from disease (44, 45). Clearly, the identification of new malaria vaccine candidates will benefit the vaccine development effort and might be crucial if current candidates fail to confer protective immunity.

Disabling immunity. As described above, results from seroepidemiology studies indicate that immunity to malaria is slow to develop and is incomplete. For example, in young children the process of acquiring a specific Ab response to a defined parasite Ag is slow, and such responses, once acquired, can be short lived (in the order of days) and may not be recalled upon reinfection (46). This short half-life of acquired immunity to parasite Ags is in stark contrast to many other infectious diseases. For example, the estimated half-life of Ab responses to viruses ranges from 50 years for varicella-zoster virus to >200 years for the viruses that cause measles and mumps (47).

How might malaria interfere with immune function and the acquisition or maintenance of immunological memory? Hundreds of parasite products are released from lysed RBC (48, 49), most of which are of unknown function but could potentially interfere with the immune response. At least two of these products interact with the innate immune system's TLRs, and TLRs have been implicated in playing a role in the generation and maintenance of B cell memory (50). RBC lysis results in the release of glycosylphosphatidylinositol, which is recognized by TLR2 and to some extent by TLR4 (51). A second product that is released by ruptured parasitized RBC is hemozoin, a detoxified crystalline form of heme produced by the parasite that has been suggested to be a TLR9 agonist (52), although this is controversial (53). A possible mechanism by which immunological memory might be disabled was indicated by the results of studies in a mouse model in which parasite-specific memory B cells generated by immunization with parasite proteins were observed to undergo apoptosis when the mouse was infected with a malaria parasite (54). Are there any clues from other chronic infections in humans as to how *P. falciparum* might interfere with immunity? For example, T cell exhaustion or loss of function is a common feature of many chronic human infections, including HIV and hepatitis B and C (55). An exhausted B cell phenotype has also been described recently for memory B cells

in HIV-infected individuals (56). The possibility that in malaria the continued presence of the parasite drives parasite-specific T cells and B cells into an exhausted phenotype should be explored.

To better understand how malaria affects the immune system, it might be possible to mine the human genome for genetic traits that confer resistance to malaria infection and disease (5, 6). As described above, malaria has shaped the human genome to a greater extent than any other pathogen. Understanding how the human genome has adapted to coexist with malaria parasites could provide new insights into the mechanisms of both the innate and adaptive immune systems that underlie resistance to severe disease and death. Whole genome-wide screens for malaria resistance alleles by genetic association analysis now seem to be feasible (5). There are also well-described differences between ethnic groups living sympatrically in malaria-endemic areas in which members of one group, for example the Fulani in Mali and Burkina Faso, have significantly lower parasite rates compared with other ethnic groups (57). Several immune parameters have been compared between these groups, but we still have an incomplete understanding of what differences are key to protection. In terms of candidate gene analyses, of particular interest are genes that confer susceptibility to the systemic autoimmune disease, especially systemic lupus erythematosus (SLE), a disease for which women of African descent are significantly at risk. It is possible that polymorphisms in genes of the immune system that confer resistance to disease and death caused by malaria might, in nonendemic areas, be susceptibility genes for autoimmunity. For example, a polymorphism in the inhibitory Fc receptor FcγRIIB, which is a susceptibility gene in SLE, was recently shown to confer resistance to malaria in a mouse model (58). Conversely, malaria infections have been shown to suppress SLE-like autoimmune disease in mice (59). We predict that such an approach might be profitable in discovering mechanisms by which malaria influences the immune response.

Conclusion

In this article we have attempted to make the case that we may not know enough about malaria to make an effective vaccine. If we agree that the development of a malaria vaccine would profit from a better understanding of the basic immunology of the human response to malaria, we then need to ask the following question: have we engaged a sufficient number of immunologists to address the problem? At the moment, probably not. Relative to the magnitude of the global disease burden imposed by malaria, there are only a small number of scientists with the training and expertise in the human immune system who are committed to working at the molecular interface of the parasite and the immune system. We believe that this interface should provide exciting careers for young scientists meeting the challenges of controlling one of the world's most deadly diseases. In the near future, we anticipate the commitment of significant additional resources from both private and public institutions for studies leading to the development of vaccines for malaria, including the National Institute of Allergy and Infectious Diseases Malaria Research Program, the Bill and Melinda Gates Foundation, the Global Fund, and the President's Malaria Initiative. We feel that the recent call for eradication of malaria by the Bill and Melinda Gates Foundation (Bill and Melinda Gates Call for New Global Commitment to Chart a Course for

Malaria Eradication) represents a call to arms of immunologists to use their knowledge of the intricate workings of the immune system to the fight to reduce the malaria death toll in African children.

Disclosures

The authors have no financial conflict of interest.

References

- Molineaux, L. 1985. The impact of parasitic diseases and their control on mortality, with emphasis on malaria and Africa. In *Health Policy, Social Policy, and Mortality Prospects*. J. Vallin, and A. Lopez, eds. Ordina Editions, Liege, Belgium, pp.13–44.
- Bhattarai, A., A. S. Ali, S. P. Kachur, A. Martensson, A. K. Abbas, R. Khatib, A. W. Al-Mafazy, M. Ramsan, G. Rollant, J. F. Gerstenmaier, et al. 2007. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. *PLoS Med.* 4: e309.
- Greenberg, A. E., M. Ntumbanzondo, N. Ntula, L. Mawa, J. Howell, and F. Davachi. 1989. Hospital-based surveillance of malaria-related paediatric morbidity and mortality in Kinshasa, Zaire. *Bull. W. H. O.* 67: 189–196.
- Mu, J., J. Duan, K. D. Makova, D. A. Joy, C. Q. Huynh, O. H. Branch, W. H. Li, and X. Z. Su. 2002. Chromosome-wide SNPs reveal an ancient origin for *Plasmodium falciparum*. *Nature* 418: 323–326.
- Ntoumi, F., D. P. Kwiatkowski, M. Diakite, T. K. Mutabingwa, and P. E. Duffy. 2007. New interventions for malaria: mining the human and parasite genomes. *Am. J. Trop. Med. Hyg.* 77: 270–275.
2008. A global network for investigating the genomic epidemiology of malaria. *Nature* 456: 732–737.
- Collins, W. E., and G. M. Jeffery. 1999. A retrospective examination of sporozoite- and trophozoite-induced infections with *Plasmodium falciparum*: development of parasitologic and clinical immunity during primary infection. *Am. J. Trop. Med. Hyg.* 61: 4–19.
- Crompton, P. D., B. Traore, K. Kayentao, S. Doumbo, A. Ongoiba, S. A. Diakite, M. A. Krause, D. Doumbo, Y. Kone, G. Weiss, et al. 2008. Sick cell trait is associated with a delayed onset of malaria: implications for time-to-event analysis in clinical studies of malaria. *J. Infect. Dis.* 198: 1265–1275.
- Miller, L. H., D. I. Baruch, K. Marsh, and O. K. Doumbo. 2002. The pathogenic basis of malaria. *Nature* 415: 673–679.
- Marsh, K., D. Forster, C. Waruiru, I. Mwangi, M. Winstanley, V. Marsh, C. Newton, P. Winstanley, P. Warn, N. Peshu, et al. 1995. Indicators of life-threatening malaria in African children. *N. Engl. J. Med.* 332: 1399–1404.
- Lackritz, E. M., C. C. Campbell, T. K. Ruebush II, A. W. Hightower, W. Wakube, R. W. Steketee, and J. B. Were. 1992. Effect of blood transfusion on survival among children in a Kenyan hospital. *Lancet* 340: 524–528.
- Hoffman, S. L., C. N. Oster, C. V. Plowe, G. R. Woollett, J. C. Beier, J. D. Chulay, R. A. Wirtz, M. R. Hollingdale, and M. Mugambi. 1987. Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. *Science* 237: 639–642.
- Alonso, P. L., J. Sacarlal, J. J. Aponte, A. Leach, E. Macete, P. Aide, B. Sigauque, J. Milman, I. Mandomando, Q. Bassat, et al. 2005. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of *Plasmodium falciparum* disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. *Lancet* 366: 2012–2018.
- Chakravarty, S., I. A. Cockburn, S. Kuk, M. G. Overstreet, J. B. Sacci, and F. Zavala. 2007. CD8⁺ T lymphocytes protective against malaria liver stages are primed in skin-draining lymph nodes. *Nat. Med.* 13: 1035–1041.
- Singh, A. P., C. A. Buscaglia, Q. Wang, A. Levay, D. R. Nussenzweig, J. R. Walker, E. A. Winzler, H. Fujii, B. M. Fontoura, and V. Nussenzweig. 2007. *Plasmodium* circumsporozoite protein promotes the development of the liver stages of the parasite. *Cell* 131: 492–504.
- Beadle, C., P. D. McElroy, C. N. Oster, J. C. Beier, A. J. Oloo, F. K. Onyango, D. K. Chumo, J. D. Bales, J. A. Sherwood, and S. L. Hoffman. 1975. Impact of transmission intensity and age on *Plasmodium falciparum* density and associated fever: Implications for malaria vaccine trial design. *J. Infect. Dis.* 172: 1047–1054.
- Nussenzweig, R. S., J. Vanderberg, H. Most, and C. Orton. 1967. Protective immunity produced by the injection of X-irradiated sporozoites of *Plasmodium berghei*. *Nature* 216: 160–162.
- Wang, R., T. L. Richie, M. F. Baraceros, N. Rahardjo, T. Gay, J. G. Banania, Y. Charoenvit, J. E. Epstein, T. Luke, D. A. Freilich, et al. 2005. Boosting of DNA vaccine-elicited γ interferon responses in humans by exposure to malaria parasites. *Infect. Immun.* 73: 2863–2872.
- Stoute, J. A., M. Slaoui, D. G. Heppner, P. Momin, K. E. Kester, P. Desmons, B. T. Wellde, N. Garcon, U. Krzych, and M. Marchand. 1997. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against *Plasmodium falciparum* malaria. RTS,S Malaria Vaccine Evaluation Group. *N. Engl. J. Med.* 336: 86–91.
- Bejon, P., J. Lusingu, A. Olotu, A. Leach, M. Lievens, J. Vekemans, S. Mshamu, T. Lang, J. Gould, M. C. Dubois, et al. 2008. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. *N. Engl. J. Med.* 359: 2521–2532.
- Cohen, S., I. A. McGregor, and S. Carrington. 1961. Gamma-globulin and acquired immunity to human malaria. *Nature* 192: 733–737.
- Maher, B. 2008. Malaria: the end of the beginning. *Nature* 451: 1042–1046.
- Gaur, D., D. C. Mayer, and L. H. Miller. 2004. Parasite ligand-host receptor interactions during invasion of erythrocytes by *Plasmodium* merozoites. *Int. J. Parasitol.* 34: 1413–1429.

24. Cowman, A. F., and B. S. Crabb. 2006. Invasion of red blood cells by malaria parasites. *Cell* 124: 755–766.
25. Sim, B. K., C. E. Chitnis, K. Wasniowska, T. J. Hadley, and L. H. Miller. 1994. Receptor and ligand domains for invasion of erythrocytes by *Plasmodium falciparum*. *Science* 264: 1941–1944.
26. Genton, B., I. Betuela, I. Felger, F. Al-Yaman, R. F. Anders, A. Saul, L. Rare, M. Baisor, K. Lorry, G. V. Brown, et al. 2002. A recombinant blood-stage malaria vaccine reduces *Plasmodium falciparum* density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. *J. Infect. Dis.* 185: 820–827.
27. Bouharrou-Tayoun, H., C. Oeuvray, F. Lunel, and P. Druilhe. 1995. Mechanisms underlying the monocyte-mediated antibody-dependent killing of *Plasmodium falciparum* asexual blood stages. *J. Exp. Med.* 182: 409–418.
28. Schofield, L., M. C. Hewitt, K. Evans, M. A. Siomos, and P. H. Seeberger. 2002. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. *Nature* 418: 785–789.
29. Weidanz, W. P., J. M. Batchelder, P. Flaherty, G. LaFleur, C. Wong, and H. C. van der Heyde. 2005. *Plasmodium chabaudi* adami: use of the B-cell-deficient mouse to define possible mechanisms modulating parasitemia of chronic malaria. *Exp. Parasitol.* 111: 97–104.
30. Perry, J. A., C. S. Oliver, R. C. Burnett, and A. C. Avery. 2005. Cutting edge: the acquisition of TLR tolerance during malaria infection impacts T cell activation. *J. Immunol.* 174: 5921–5925.
31. Kwiatkowski, D. 1990. Tumour necrosis factor, fever and fatality in falciparum malaria. *Immunol. Lett.* 25: 213–216.
32. Lyke, K. E., R. Burges, Y. Cissoko, L. Sangare, M. Dao, I. Diarra, A. Kone, R. Harley, C. V. Plowe, O. K. Doumbo, and M. B. Sztein. 2004. Serum levels of the proinflammatory cytokines interleukin-1 β (IL-1 β), IL-6, IL-8, IL-10, tumor necrosis factor α , and IL-12(p70) in Malian children with severe *Plasmodium falciparum* malaria and matched uncomplicated malaria or healthy controls. *Infect. Immun.* 72: 5630–5637.
33. Walther, M., J. Woodruff, F. Edele, D. Jeffries, J. E. Tongren, E. King, L. Andrews, P. Bejon, S. C. Gilbert, J. B. De Souza, et al. 2006. Innate immune responses to human malaria: heterogeneous cytokine responses to blood-stage *Plasmodium falciparum* correlate with parasitological and clinical outcomes. *J. Immunol.* 177: 5736–5745.
34. Roberts, D. J., A. G. Craig, A. R. Berendt, R. Pinches, G. Nash, K. Marsh, and C. I. Newbold. 1992. Rapid switching to multiple antigenic and adhesive phenotypes in malaria. *Nature* 357: 689–692.
35. Bull, P. C., B. S. Lowe, M. Kortok, C. S. Molyneux, C. I. Newbold, and K. Marsh. 1998. Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. *Nat. Med.* 4: 358–360.
36. Salanti, A., T. Staaloe, T. Lavstsen, A. T. Jensen, M. P. Sowa, D. E. Arnot, L. Hviid, and T. G. Theander. 2003. Selective upregulation of a single distinctly structured *var* gene in chondroitin sulphate A-adhering *Plasmodium falciparum* involved in pregnancy-associated malaria. *Mol. Microbiol.* 49: 179–191.
37. Fried, M., and P. E. Duffy. 1996. Adherence of *Plasmodium falciparum* to chondroitin sulfate A in the human placenta. *Science* 272: 1502–1504.
38. Fried, M., F. Nosten, A. Brockman, B. J. Brabin, and P. E. Duffy. 1998. Maternal antibodies block malaria. *Nature* 395: 851–852.
39. Stowers, A. W., M. C. Kennedy, B. P. Keegan, A. Saul, C. A. Long, and L. H. Miller. 2002. Vaccination of monkeys with recombinant *Plasmodium falciparum* apical membrane antigen 1 confers protection against blood-stage malaria. *Infect. Immun.* 70: 6961–6967.
40. Duan, J., J. Mu, M. A. Thera, D. Joy, S. L. Kosakovsky Pond, D. Diemert, C. Long, H. Zhou, K. Miura, A. Ouattara, et al. 2008. Population structure of the genes encoding the polymorphic *Plasmodium falciparum* apical membrane antigen 1: implications for vaccine design. *Proc. Natl. Acad. Sci. USA* 105: 7857–7862.
41. Collins, C. R., C. Withers-Martinez, G. A. Bentley, A. H. Batchelor, A. W. Thomas, and M. J. Blackman. 2007. Fine mapping of an epitope recognized by an invasion-inhibitory monoclonal antibody on the malaria vaccine candidate apical membrane antigen 1. *J. Biol. Chem.* 282: 7431–7441.
42. Serruto, D., and R. Rappuoli. 2006. Post-genomic vaccine development. *FEBS Lett.* 580: 2985–2992.
43. Davies, D. H., X. Liang, J. E. Hernandez, A. Randall, S. Hirst, Y. Mu, K. M. Romero, T. T. Nguyen, M. Kalantari-Dehaghi, S. Crotty, et al. 2005. Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. *Proc. Natl. Acad. Sci. USA* 102: 547–552.
44. Gray, J. C., P. H. Corran, E. Mangia, M. W. Gaunt, Q. Li, K. K. Tetteh, S. D. Polley, D. J. Conway, A. A. Holder, T. Bacaese-Hamilton, et al. 2007. Profiling the antibody immune response against blood stage malaria vaccine candidates. *Clin. Chem.* 53: 1244–1253.
45. Doolan, D. L., Y. Mu, B. Unal, S. Sundaresh, S. Hirst, C. Valdez, A. Randall, D. Molina, X. Liang, D. A. Freilich, et al. 2008. Profiling humoral immune responses to *P. falciparum* infection with protein microarrays. *Proteomics* 8: 4680–4694.
46. Kinyanjui, S. M., D. J. Conway, D. E. Lanar, and K. Marsh. 2007. IgG antibody responses to *Plasmodium falciparum* merozoite antigens in Kenyan children have a short half-life. *Malar. J.* 6: 82.
47. Amanna, I. J., N. E. Carlson, and M. K. Slifka. 2007. Duration of humoral immunity to common viral and vaccine antigens. *N. Engl. J. Med.* 357: 1903–1915.
48. Hiller, N. L., S. Bhattacharjee, C. van Ooij, K. Liolios, T. Harrison, C. Lopez-Estrano, and K. Haldar. 2004. A host-targeting signal in virulence proteins reveals a secretome in malarial infection. *Science* 306: 1934–1937.
49. Marti, M., R. T. Good, M. Rug, E. Knuepfer, and A. F. Cowman. 2004. Targeting malaria virulence and remodeling proteins to the host erythrocyte. *Science* 306: 1930–1933.
50. Bernasconi, N. L., N. Onai, and A. Lanzavecchia. 2003. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. *Blood* 101: 4500–4504.
51. Nebl, T., M. J. De Veer, and L. Schofield. 2005. Stimulation of innate immune responses by malarial glycosylphosphatidylinositol via pattern recognition receptors. *Parasitology* 130(Suppl.): S45–S62.
52. Coban, C., K. J. Ishii, T. Kawai, H. Hemmi, S. Sato, S. Uematsu, M. Yamamoto, O. Takeuchi, S. Itagaki, N. Kumar, et al. 2005. Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. *J. Exp. Med.* 201: 19–25.
53. Parroche, P., F. N. Lauw, N. Goutagny, E. Latz, B. G. Monks, A. Visintin, K. A. Halmen, M. Lamphier, M. Olivier, D. C. Bartholomeu, et al. 2007. Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. *Proc. Natl. Acad. Sci. USA* 104: 1919–1924.
54. Wykes, M. N., Y. H. Zhou, X. Q. Liu, and M. F. Good. 2005. *Plasmodium yoelii* can ablate vaccine-induced long-term protection in mice. *J. Immunol.* 175: 2510–2516.
55. Shin, H., and E. J. Wherry. 2007. CD8 T cell dysfunction during chronic viral infection. *Curr. Opin. Immunol.* 19: 408–415.
56. Moir, S., J. Ho, A. Malaspina, W. Wang, A. C. DiPoto, M. A. O'Shea, G. Roby, S. Kottitil, J. Arthos, M. A. Proschan, et al. 2008. Evidence for HIV-associated B-cell exhaustion in a dysfunctional memory B-cell compartment in HIV-infected viremic individuals. *J. Exp. Med.* 205: 1797–1805.
57. Modiano, D., V. Petrarca, B. S. Sirima, I. Nebie, D. Diallo, F. Esposito, and M. Coluzzi. 1996. Different response to *Plasmodium falciparum* malaria in West African sympatric ethnic groups. *Proc. Natl. Acad. Sci. USA* 93: 13206–13211.
58. Clarworthy, M. R., L. Willcocks, B. Urban, J. Langhorne, T. N. Williams, N. Peshu, N. A. Watkins, R. A. Floto, and K. G. Smith. 2007. Systemic lupus erythematosus-associated defects in the inhibitory receptor Fc γ RIIb reduce susceptibility to malaria. *Proc. Natl. Acad. Sci. USA* 104: 7169–7174.
59. Greenwood, B. M., E. M. Herrick, and A. Voller. 1970. Suppression of autoimmune disease in NZB and (NZB \times NZW)F $_1$ hybrid mice by infection with malaria. *Nature* 226: 266–267.